Three Amgen manufacturing sites, along with Pfizer’s Perth, Australia site are part of a list of more than 100 US FDA Form 483s issued so far in 2015, according to a list obtained by In-Pharmatechnologist.com thanks to the FOIA (Freedom of Information...
Swiss drug major Roche is facing a delay in bringing its EPO drug
Mircera (continuous erythropoietin receptor activator) to market in
the US after the Food and Drug Administration sent it an
'approvable' notice for the product.
The decision of the US Supreme Court not to hear Amgen's appeal in
a patent infringement case against Sanofi-Aventis and Shire,
involving the anaemia drug Epogen (epoetin alfa), may weaken
Amgen's position in keeping another...
Predix Phamaceuticals has formed a collaboration with Amgen in a
deal that aims to develop S1P1 modulators for the treatment of
autoimmune diseases. The agreement has the potential to become a
$300m (€235m) payout for Predix.
Biotechnology company, Amgen, and Biovitrum have expanded its
existing license agreement for its treatment of metabolic
disorders, focusing on type 2 diabetes, which currently afflicts
over 160 million people worldwide.
Responding to growing demand, Biotechnology giant Amgen has
announced an expansion of its manufacturing facilities in Puerto
Rico, investing $1 billion (€835 million) in the project over the
next four years.
Amgen are to create a European Development Centre in the UK,
significantly increasing UK R&D employee numbers. Amgen's
announcement echoes the UK Government's commitment to attract more
R&D investment with a view...
Amgen are to create a European Development Centre significantly
boosting UK drug R&D. The announcement echoes the UK
Government's commitment to attract more R&D investment with a
view to making the UK a leader in biotechnology.
Pharmaceutical companies are set to face stiff competition, as
generic forms of best-selling biologic drugs will capture a
significant market share. The expiration of drug patents, which
expire within the next few years, opens up...
Two $500m-plus licensing deals reveal the rewards available to
biotech firms with novel drugs, but also the lengths large
biopharma companies will now go to secure exclusive rights to
promising candidates, even if they are in the...